NCT00637221

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Neuropharm · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This is an open label exploratory study to investigate the safety and effects of a single dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous Performance Tasks (CPT) in adults with Fragile X Syndrome

Conditions

• Fragile X Syndrome

Interventions

Type	Name	Description
DRUG	NPL-2009	Single doses of either 50mg, 100 mg or 150 mg NPL-2009

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-04-01
• Completion: 2008-04-01
• First posted: 2008-03-17
• Last updated: 2012-04-27

Locations

2 sites across 1 country: United States